Bharat Biotech is set to start phase-III trials for an anti-cholera vaccine – Hillchol. The company is looking at producing at least 50 million doses of the vaccine in the coming 3-4 years. The company is in the process of seeking a technology transfer from Hilleman Laboratories.
In Phase-I studies, the company established the safety of the vaccine with an age descending trial starting from adults of 55 years.
Currently, the anti-cholera vaccine is missing from the Universal Immunization Programme of the Union Health Ministry Nearly 30 per cent of Indian population is at risk of getting infected from cholera. Globally, cholera accounts for 28 lakh cases and 95,000 deaths annually.
Company Profile : Bharat Biotech Ltd